Methods of treating fibrosis
Disclosed are methods of treating fibrosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of an ACK inhibitor (e.g., a BTK inhibitor, such as for example an irreversible BTK inhibitor, such as for example, ibrutinib).
1. A method of treating fibrosis, wherein the fibrosis is not associated with graft versus host disease (GVHD), comprising administering to a patient having fibrosis, wherein the fibrosis is not associated with GVHD, a therapeutically effective amount of a compound, which is 1-(R)-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib), of the structure:
thereby treating the fibrosis.
2. The method of claim 1 , wherein the fibrosis is of the liver, lung, kidney, bone marrow, heart, skin, intestine, or joints.
3. The method of claim 1 , wherein the fibrosis is of the liver.
4. The method of claim 1 , wherein the fibrosis is of the lung.
5. The method of claim 1 , wherein the patient has cirrhosis, or cystic fibrosis.